let-7 MicroRNAs Induce Tamoxifen Sensitivity by Downregulation of Estrogen Receptor α Signaling in Breast Cancer
- 7 Downloads
MicroRNAs (miRNAs) play an important regulatory role in breast tumorigenesis. Previously, we found that let-7 miRNAs were downregulated significantly in formalin-fixed paraffin-embedded (FFPE) breast cancer tissues. In this study, we further found that endogenous levels of let-7b and let-7i miRNAs are inversely correlated with levels of estrogen receptor (ER)-a36, a new variant of ER-α66, in the FFPE tissue set. Bioinformatic analysis suggested that ER-α36 may be another target of let-7 miRNAs. To test this hypothesis, cotransfection of let-7 mimics or inhibitors together with full-length or a fragment of ER-α36 3′UTR luciferase construct was performed, and we found that let-7b and let-7i mimics suppressed the activity of reporter gene significantly, which was enhanced remarkably by let-7b and let-7i inhibitors. Both mRNA and protein expression of ER-α36 were inhibited by let-7 mimics and enhanced by let-7 inhibitors. Furthermore, ER-α36 mediated nongenomic MAPK and Akt pathways were weakened by let-7b and let-7i mimics in triple negative breast cancer cell line MDA-MB-231. The reverse correlation between let-7 miRNAs and ER-α36 also exists in Tamoxifen (Tam)-resistant MCF7 cell line. Transfection of let-7 mimics to Tam-resistant MCF7 cells downregulated ER-α36 expression and enhanced the sensitivity of MCF7 cells to Tam in estrogen-free medium, which could be restored by overexpression of ER-α36 constructs without 3′UTR. Our results suggested a novel regulatory mechanism of let-7 miRNAs on ER-α36 mediated nongenomic estrogen signal pathways and Tam resistance.
The involvement of estrogen in mammary carcinogenesis has been known for more than 100 years (1). For a long time, the estrogen signaling was thought to be mediated by two major estrogen receptors (ER), ER-α and ER-β (2), which share a common structural architecture. ER-a is a 66 kD protein that functions as a transcription factor and regulates the transcription of estrogen-responsive genes. ER-α is comprised of six domains, A–F (3). The A/B region contains a ligand-independent transactivation domain (AF-1). Regions C and E are responsible for DNA and ligand binding, respectively. A ligand-inducible transcription-activating function (AF-2) is present in the ligand-binding domain D/E/F (4). Recent research revealed the existence of a truncated form of ER-α with a molecular weight of 46 kD, which lacks the first 173 aa (AF-1 domain) of ER-α and is designated as ER-α46 (5). The full-length ER-a therefore is recognized as ER-α66. ER-α46 functions to inhibit the transcriptional activity mediated by the AF-1 domain of ER-α66 (5) and to signal a membrane-initiated estrogen pathway (6).
Later, a 36-kD novel isoform of ER-α66, ER-α36, was identified and cloned (7). The full-length cDNA accession number is BX640939. This cDNA is localized in the human genomic DNA sequence of clone RP1-130E4 on chromosome 6q24.2–25.3 (GenBank Accession Number AL078582) (7). ER-α36 is transcribed from a promoter located in the first intron of the ER-α66 gene and lacks both transcriptional activation domains (AF-1 and AF-2), but retains the DNA-binding, dimerization and partial ligand-binding domains. Additionally, it possesses an extra, unique 27-aa domain to replace the last 138 aa of the ER-α66. ER-α36 is localized predominantly on the plasma membranes and mediates membrane-initiated estrogen signal pathway (8) such as activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway (9). ER-α36 expression was detected in both ER-α66-positive and-negative breast cancer tumors (10,11). High levels of ER-α36 expression also are associated with tamoxifen resistance; breast cancer patients with tumors highly expressing ER-α36 benefit less from tamoxifen treatment (12).
Dysregulated miRNA expression is associated frequently with the development of many types of human tumors. It was reported that almost half of the known mature human miRNAs are located in cancer-associated genomic regions, or fragile sites (13). The let-7 family is considered as a tumor suppressor to inhibit malignant growth of many types of cancer cells by targeting RAS (14), HMGA2 (15,16) and c-Myc (17). Reduced expression of let-7 miRNA has been reported in cancers of colon (18), lung (19), ovary (20) and breast (21).
In this study, we found a novel regulatory relationship between let-7 miRNAs and ER-α36. We demonstrated that there is an inverse correlation between ER-α36 and let-7 miRNAs in breast tissue and in the tamoxifen-resistant cell line. let-7 miRNAs target ER-α36 and negatively regulate its expression and function. In addition, let-7 miRNAs (b and i) enhanced tamoxifen sensitivity of tamoxifen-resistant breast cancer cells by targeting ER-α36 expression.
Material and Methods
All breast cancer cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The normal breast cell line 184A1 was cultured in 10% Fetal Bovine Serum (FBS; Gibco, Carslbad, CA, USA) and MEGM (MEBM plus SingleQuots; Clonetics, Walkersville, MD, USA). ER-positive breast cancer cell lines, MCF7, ZR-75-1, T47D and HB3396 were maintained in phenol-red free IMEM (Cellgro) plus 10% FBS, 1% nonessential amino acid, 10 mmol/L HEPES and 2 µg/mL insulin. MDA-MB-231, MDA-MB-436, MDA-MB-468 and SK-BR-3 were cultured in DMEM (Cellgro) plus 10% FBS. Tamoxifen-resistant MCF7 cell line (MCF7-Tam) was established by culturing ER-positive breast cancer MCF7 cells in 1 µmol/L tamoxifen over 6 months and maintaining them in IMEM plus 1 µmol/L tamoxifen (22). All cells were incubated at 37°C with 5% CO2 atmosphere.
Quantitative Real-Time PCR
To analyze mature let-7 miRNAs with real-time polymerase chain reaction (PCR), total RNA was isolated from the cell lines using mirVana miRNA isolation kit (Ambion Inc., Austin, TX, USA) or from FFPE tissues using the miRNeasy FFPE Kit (Qiagen, Valencia, CA, USA) following the manufacturer’s instructions. We collected FFPE breast tissues from 13 benign, 16 ductal carcinomas in situ (DCIS) and 15 invasive ductal carcinomas (IDC), all of which were prepared as 50-µm-thick sheets. The benign breast tissues were from surgical resections of abnormal breast lesions with non-neoplastic phenotypes such as calcification, fibrocystic changes or stromal fibrosis. cDNA was synthesized using 100 ng total RNA in a reaction volume of 15 µL and following the protocol of Taqman microRNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). After 15× dilution, 9 µL cDNA was used for real-time PCR in 20 µL reaction volume, including 10 µL of TaqMan universal PCR master mix (no ampErase UNG) and 1 µL primer mixture and Taqman probe (Applied Biosystems, Foster City, CA, USA). Realtime PCR was performed on 7900HT realtime PCR instrument (Applied Biosystems). PCR was initiated by two holds of 52°C 2 min and 94°C 10 min each, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. The level of each miRNA was expressed following the 2−ΔΔCt or −ΔCt method using the small nuclear RNA RNU48 as the internal reference.
To assess the expression levels of ER-α66 and ER-α36 with real-time PCR, total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA). One microgram RNA was used for cDNA synthesis with the SuperScript III first-strand synthesis system (Invitrogen). After 10× dilution, 4 µL cDNA was used in 20 µL reaction volume, which includes 4 µL of 1.5 µmol / L primers, 2 µL of 2 µmol/L probes, and 10 µL TaqMan universal PCR master mix with ampErase UNG (Applied Biosystems). The reaction condition was the same as miRNA real-time PCR. β-Actin was the internal control (Applied Biosystems). The primers for ER-α66 are: 5′-GCGGC CACGGACCAT-3′ (forward); 5′-TTCCC TTGGATCTGATGCAGTA-3′ (reverse); 5′-FAM-CCATGACCCTCCACACCAAA GCATC-TAMRA-3′ (probe). The primers for ER-α36 are: 5′-CAAGTGGTTTCCTC GTGTCTAAAG-3′ (forward); 5′-ACGTC CACACACGGATTTGA-3′ (reverse); 5′-FAM-TGGTCATAAGGCCTCACAGT ATCCTGCA-TAMRA-3′ (probe).
Transient miRNA Transfection for Western Blot and Growth Analysis
let-7 miRNA or negative control #1 miRNA of 60 nmol/L, inhibitor or inhibitor negative control #1 of 200 nmol/L (let-7b, Cat# PM11050; let-7i, Cat# PM10211; negative #1 AM17110; let-7b inhibitor, AM11050; let-7i inhibitor, AM10211; inhibitor negative control #1, AM17010) (Ambion) was transfected into cells with the siPORT NeoFX reagent (Ambion) following the manufacturer’s protocol.
Western Blot Analysis
Cells were lysed with NP40 cell lysis buffer (250 mmol/L NaCl, 50 mmol/L Tris-HCl, pH 7.4, 5 mmol/L EDTA, 50 mmol/L NaF, 1 mmol/L Na3VO4, 1% Nonidet P40, 1 mmol/L PMSF, proteinase and phosphoproteinase inhibitor cocktails). For protein extraction from FFPE tissues, FFPE sections (50 µm thick) were transferred into a microcentrifuge tube and treated with xylene, followed by vortexing vigorously for 10 s. After centrifugation and removal of supernatant, the sections were washed with xylene for two more times, followed by one more wash with 1 mL of 100% ethanol. The resultant pellets were vacuum dried, then resuspended in 300 µL of 20 mmol/L Tris-HCl (pH 8.0) and 2% SDS and homogenized. The samples were then boiled at 100°C for 20 min and incubated at 60°C for 1 h. After centrifugation at 10,000g for 15 min at 4°C, the supernatant protein was saved for immunoblot analysis.
The quantified protein of 50 µg was mixed with gel-loading buffer and boiled for 5 min before loading onto 10% SDS-PAGE. After electrophoresis, the gel was blotted onto a PVDF membrane (Millipore, Billerica, MA, USA). The blots were probed with specific first antibodies and appropriate second antibodies. The signals were visualized with enhanced chemiluminescence (ECL) reagents (Pierce, Minneapolis, MN, USA) and documented with a FluorChem FC2 (Alpha Innotech, Santa Clara, CA, USA) image system. Gel density was quantified with Quantity One and expressed as a relative value against β-actin. The sources of antibodies are as follows: anti-ERK1/2 (#9102), anti-pERK1/2 (#9106), anti-Akt (#9272), anti-pAkt (Ser473, #9271), and anti-Her2 (#2242) are from Cell Signaling Technology (Danvers, MA, USA); anti-ER-α66 (RB-9016) was from Thermoscientific (Rockford, IL, USA); anti-ER-α36 antibody was an affinity-purified rabbit polyclonal anti-ER-36 antibody generated as a custom service from Pacific Immunology Corp (Ramona, CA, USA). The ER-α36 antibody was raised against a synthetic peptide antigen corresponding to the unique C-terminal 20 aa of ER-α36.
QIAGEN Long Range 2 Step RT-PCR Kit (Qiagen, Cat# 205920) was used to amplify ER-α36 3′UTR. The PCR primers are as follows: CATGTAGCACTAGTC ATCAAATCCGTGTGTGGAC (forward); CATGTAGCACGCGTTATCCCCACAG CATTCCTTC (reverse). The PCR product was applied to agarose gel electrophoresis, gel-purified with QIAquick Gel Extraction Kit (Qiagen, Cat# 28704), digested with SpeI and MluI (Promega, Fitchburg, WI, USA), and purified with QIAquick PCR Purification Kit (Qiagen, Cat# 28104). The pMIR-Report plasmid (Applied Biosystems) also was digested with SpeI and MluI, and gel-purified. The ligation was performed with T4 ligase (Promega) in 10 µL volume. One µL of ligation product was transformed into DH5a Competent E. coli cells (Invitrogen, Cat# 18265-017). Positive clones were picked, amplified in LB broth with 100 µg/mL ampicillin. Reconstructed plasmids were extracted with EndoFree Plasmid Maxi Kit (Qiagen, Cat# 12362). The correct insert was verified by sequencing.
The full-length ER-α36 construct with mutated binding site for let-7 miRNAs was generated with Quik Change Site-Directed Mutagenesis Kit (Cat# 200519; Agilent Technologies, Santa Clara, CA, USA). The sense primer was CTAGAAACACCAGGA AGGCA GCAAGAAAATAGCAACAGAG AAACC; the antisense primer was GGTTT CTCTGTTGCTATTTTCTTGCTGCCT TCCTGGTGTTTCTAG.
Transfection was performed in 24-well plate using Lipofectamine 2000 (Invitrogen) in triplicate (23). let-7 mimics, anti-let-7 inhibitors, or negative controls were transfected with 0.25 µg luciferase construct and 0.25 µg β-galactosidase plasmid (Ambion) to check transfection efficiency. Twenty-four h after transfection, the luciferase activity was measured using Dual-Glo Luciferase Assay System (Promega) in Veritas Microplate Luminometer (Turner Biosystems, Sunnyvale, CA, USA).
MTT Cell Proliferation Assay
MCF7-Tam cells were transfected with let-7 mimics or negative control in normal growth medium for 1 d, or in medium with 2.5% charcoal-stripped FBS for 2 d to exhaust endogenous estrogen. Ten thousand cells in the volume of 100 µL were seeded in a 96-well plate for 12 h and assay lasted for another 4 d. For tamoxifen treatment, 1 µmol/L tamoxifen was added into the growth medium. Each treatment had 12 repeats on the plate. Medium volume was increased to 200 µL after the assay began. At certain time points, the cells were incubated in 0.83 mg/mL 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) in growth medium at 37°C for 4 h and lysed in 100 µL of dimethyl sulfoxide at room temperature for 15 min. The absorbance in each well was measured at 490 nmol/L with an ELx800 Absorbance Microplate Reader (Biotek, Winooski, VT, USA). Cell growth was expressed as a fraction of absorbance at d 0.
The correlation between let-7 miRNA expression and ER-α36 was analyzed in SPSS 16.0 (SPSS Inc., Chicago, IL, USA). For comparison among means of different treatments, one-way analysis of variance (ANOVA) with the Tukey’s adjustment was used for multiple comparisons in SPSS 16.0. *represents P < 0.05; ** represents P < 0.01.
All supplementary materials are available online at www.molmed.org .
ER-α36 Is Widely Expressed in Breast Cancer Cell Lines
let-7 MiRNAs Target ER-α36
Recently, we reported that the let-7 family miRNAs are involved in regulation of ER-α66 expression (23). To examine if let-7 miRNAs also regulate ER-α36 expression, we extracted proteins and total RNAs from 45 cases of FFPE breast cancer samples and assessed the expression levels of ER-α36 and let-7 miRNAs with Western blot and real-time PCR analysis, respectively. We found an inverse correlation between ER-α36 expression and two members of let-7 family miRNAs (let-7b and let-7i) (Figure 2B).
A strong complementary match was found between let-7 miRNAs and 3′UTR of ER-α36 gene (see Figure 1A); let-7 miRNAs match the 3,421 to 3,442 region located in the 3′UTR of ER-α36 gene. Since ER-α36 is not included in the databases used by the available softwares that predict potential miRNA-mRNA interaction, the complete sequence of ER-α36 mRNA is shown in Supplementary Table 1, in which the coding sequence, 3′ UTR, and let-7 miRNA binding site are highlighted. The ΔG of the RNA duplex is −15.8 kcal/mole between the 3′UTR of ER-α36 and let-7i (https://doi.org/mobyle.pasteur.fr/cgi-bin/portal.py?form=mfold).
To determine whether ER-α36 expression is subjected to regulation of let-7 miRNAs, we employed two strategies for luciferase assay. At first, the putative binding and flanking sequences in the 3′ UTR of ER-α36 was cloned into the 3′UTR of luciferase in the pMIR-REPORT plasmid. Cotransfection assays with 60 nmol/L let-7 miRNA mimics in MCF7 cells showed that both let-7b and let-7i potently decreased the luciferase activity, to about 60% of the activity in the control cells transfected with nonfunctional negative control miRNA (Figure 1B). Mutations in the putative let-7 miRNAs binding sequences in the 3′ UTR of ER-α36 abrogated the inhibitory effects of these miRNAs (see Figure 1B). The effect of let-7 inhibitors also was tested in cotransfection assays in the normal mammary epithelial 184A1 cell line that expresses high levels of let-7 miRNAs (24). We found that let-7b and let-7i inhibitors strongly increased the activity (2- to 3-fold) of the luciferase reporter gene carrying the putative binding site from the 3′ UTR of ER-α36 gene (Figure 1C). Again, when the binding site was mutated, let-7b or let-7i inhibitor could no longer boost the expression of luciferase (see Figure 1C).
With the concern that secondary structure might interfere with the interaction between let-7 miRNA and ER-α36 3′UTR (25), we later cloned the entire ER-α36 3 UTR of about 4 kb into pMIR-REPORT plasmid. The primer regions are highlighted in Supplementary Table 1. Similar results were generated with the entire 3′UTR of ER-α36 (Figures 1D, E). In MCF7 cells, let-7 miRNAs could inhibit the luciferase activity (about 50% of control). However, when the binding site was mutated (see Figure 1A), there was no more inhibition by let-7 miRNAs (see Figure 1D). In 184A1 cells, let-7b or let-7i inhibitors could boost the luciferase activity about 2.5-fold. However, when the binding site was mutated, there was no more increase in luciferase activity when let-7 inhibitors were added (see Figure 1E).
Effect of let-7 MiRNAs on ER-α36 Expression and Nongenomic Signal Pathways
ER-α36 is mainly localized on the plasma membrane and mediates the nongenomic estrogen pathways (7,8). We reasoned that the inhibition on ER-α36 expression by let-7 family miRNAs might dampen the nongenomic estrogen pathway. To test this hypothesis, we examined the activation of the MAPK/ERK and PI3K/Akt signaling pathways by estrogen in cells transfected with let-7 miRNAs. The MDA-MB-231 cells transfected with let-7b and let-7i mimics or negative control were cultured in 2.5% charcoal-stripped FBS for 48 h and starved in serum-free medium for another 24 h. The transfected cells then were treated with 10 nmol/L of estradiol (E2) and the activation of ERK1/2 and Akt was examined with Western blot analysis using phos-ERK and phos-Akt specific antibodies. Transfection of let-7b and let-7i significantly inhibited estrogen-induced activation of the ERK1/2 (Figure 3D) and Akt (Figure 3E), presumably through downregulation of ER-α36 expression. This result indicates that let-7 miRNAs is involved in regulation of the nongenomic estrogen pathway.
let-7 MiRNA and ER-α36 Expression in the MCF7-Tam Cell Line
Recently, it was reported that the enhanced expression of ER-α36 is involved in tamoxifen resistance (12). We then examined the tamoxifen sensitivity in tamoxifen-resistant MCF7-Tam cells transfected with let-7 miRNAs or negative control miRNA. When grown in complete medium, which contained estrogen, no difference was detected between let-7 transfection and negative control transfection (Figure 6E) with tamoxifen in the medium. However, when grown in E2-free medium, those cells transfected with let-7b or let-7i grew significantly slower than those transfected with negative control miRNA when tamoxifen was added in the medium (Figure 6F), which demonstrates that let-7 miRNAs increase tamoxifen sensitivity by decreasing ER-α36 expression. This hypothesis was validated further by the coectopic expression of ER-α36 construct, which lacks 3′UTR, so that let-7 miRNAs can no longer suppress its expression, and let-7 miRNAs (see Figure 6F). When either let-7b or let-7i was cotransfected together with ER-α36 expression vector, the sensitivity toward tamoxifen caused by high expression of let-7 miRNAs was largely nullified by high ectopic expression of ER-α36 protein (see Figure 6F). Therefore, the tamoxifen resistance in the MCF7-tam cell line is mainly due to high expression of ER-α36, which is at least partially caused by low expression of ER-α36 suppressor let-7 miRNAs.
ER-α36 is the product of a transcript initiated from the promoter located in the first intron of ER-α66 gene. ER-α36 is expressed in tumor tissues from ER-α66 positive and negative breast cancer patients (12). Thus, breast cancer patients who are clinically characterized as ERnegative (lack of the nuclear ER-α66 expression) may still express ER-α36 (12,8). ER-α36 inhibits the transcription regulatory function of ER-α66 and ER-β (8) while ER-α66 downregulates the promoter activity of ER-α36 (27). We also found that ER-α36 was expressed in both ER-α66 positive and negative cell lines (see Figure 2A), indicating its important function in breast cancer.
let-7 family miRNAs are the first miRNAs discovered in human (28), and play important roles in maintaining stemness (21). Dysregulated let-7 miRNA expression is involved in carcinogenesis (29). The expression of let-7 miRNAs increases with differentiation and cancer development (21). The low level of let-7 miRNAs in stem cells is caused by uridylation mediated by Lin28 in concert with TUT4 (30,31). Because cancer cells have similar stemness as stem cells, let-7 miRNAs are downregulated in many types of cancers, including breast cancer (18–21,32–33). Some targets of the let-7 family have been found, including Ras, HMGA2 and c-Myc (14, 15, 16). Previously, we found that the let-7 family miRNAs target ER-α66 and down-regulates its expression (24), suggesting that let-7 miRNAs play an important role in the development of ER-α66 positive breast cancer. In this study, we present strong evidence to demonstrate that let-7 miRNAs also regulate a variant of ER-α66, ER-α36. The luciferase assay with the reporter gene harboring 3′UTR of ER-α36 indicated that let-7 miRNAs directly regulate ER-α36 expression (see Figure 1). Although overexpression of let-7 miRNAs could achieve a high level (over 300-fold, see Figure 3C), the inhibition on luciferase activity was less than 50% (see Figures 1B, D) while miRNA inhibitor could boost the luciferase activity 2~3-fold (see Figures 1C, E) and only inhibited the corresponding miRNA 5-fold (see Figures 4C, F). We offer the following explanations. First, a specific miRNA inhibitor can inhibit a family of miRNAs. We checked the effect of anti-let-7a, anti-let-7b and anti-let-7i on the expression of let-7a, let-7b and let-7i in 184A1 cells (Supplementary Figure 1). Anti-let-7a not only inhibited the expression of let-7a, but also the level of let-7b and let-7i. Similar results were seen in anti-let-7b and anti-let-7i. We can reasonably deduce that the inhibitor for one family member of let-7 can inhibit the levels of other family members, although the inhibitory effect may vary. In addition, the suppression of luciferase was done in the MCF7 cell line because it has a low expression of let-7, and the stimulation of luciferase was performed in the 184A1 cell line because it has a relatively high expression of let-7.
The findings of inverse correlation between the expression of let-7 and ER-α36 (see Figure 2B), and the downregulation of ER-α36 by let-7 miRNA transfection (see Figures 3A, B) demonstrated that let-7 family miRNAs regulate ER-α36 expression. Although there are previous studies that ER-α36 inhibits the transcription regulatory function of ER-α66 (8) while ER-α66 downregulates the promoter activity of ER-α36 (27), we do not observe any correlation between the expression of ER-α66 and ER-α36 in the FFPE sample set (data not shown), consistent with other studies (10,12). The results that let-7 miRNA transfection impeded the nongenomic estrogen pathway (see Figures 3D, E) and enhances tamoxifen sensitivity in MCF7-Tam cells (see Figure 6) further indicates that let-7 family miRNAs also regulate estrogen and antiestrogen signaling, presumably through regulation of ER-α36 expression. Previous study shows that the knockdown of GPR30 does not affect nongenomic estrogen pathway, but knockdown of ER-α36 significantly affects nongenomic estrogen pathway (34). The compound G1, which was regarded as the ligand of GPR30 actually binds to ER-α36. In addition, ER-α36 binds to estrogen in vitro (34). Our experiment strengthens the concept that ER-α36 was the membrane estrogen receptor which mediates nongenomic estrogen pathway, because knockdown of ER-α36 by let-7 significantly decreases the phosphorylation of ERK and Akt, which are critical components of MAPK and PI3K pathways (see Figure 3).
Tamoxifen is the most successful adjuvant therapy drug for ER-positive breast cancer patients. It is well known that tamoxifen acts as both agonist and antagonist of estrogen signaling. The acquired and de novo tamoxifen resistance in breast cancer patients is a significant clinical problem. Our current study revealed that MCF7-Tam cells exhibits enhanced expression of ER-α36 and decreased expression of ER-α66 (see Figures 5A–C), suggesting that ER-α36 is involved in tamoxifen resistance. Previous study showed that tamoxifen acts as an agonist in ER-α36-expressing cells by activation of the MAPK/ERK signaling pathway (8), and patients who have expression of both ER-α66 and ER-α36 will benefit less from tamoxifen treatment (12). Here, we found that let-7 family miRNAs are downregulated in MCF7-Tam cells that have an enhanced expression of ER-α36 (see Figure 5D). The transfection of let-7b and let-7i miRNA not only inhibited the expression of ER-α36, but also enhanced the tamoxifen sensitivity in MCF7-Tam cells (see Figure 6F). The tamoxifen resistance can be restored by simultaneous overexpression of ER-α36 construct, which lacks 3′UTR (see Figure 6F). Therefore, our study indicates that downregulation of let-7 miRNAs causes upregulation of ER-α36, which causes tamoxifen resistance. ER-α36 is an important predictive marker for tamoxifen therapy in ER-α66 positive breast cancer patients. In fact, tamoxifen can cause more endurable ERK phosphorylation than estrogen in ER-α36 expressing cells (8). In our previous study, we conclude that there is an inverse correlation between the expression of ER-α66 and let-7 miRNAs when we compared benign tissues and ER-α66 positive breast cancer tissues (24). We did not check whether this inverse correlation exists between ER-α66 positive and negative breast cancer tissues because we did not have enough ER-α66 negative breast tissues (24). In this study, we observe a direct relationship between ER-α66 and let-7 miRNAs between MCF7 and MCF7-Tam cells (see Figure 5A, B, D). This is not surprising because let-7 miRNAs may help to upregulate the expression of ER-α66 during the transition of normal cells into breast cancer cells, but may not be decisive in the downregulation of ER-α66 during the process of ER-α66 positive breast cancer into ER-α66 negative breast cancer due to the fine tuning nature of the regulatory function of miRNAs (35,36). The mechanisms for downregulation of the expression of ER-α66 in this process are unknown.
let-7 miRNAs regulate the expression of ER-α36, resulting in enhanced sensitivity to tamoxifen treatment in breast cancer. let-7 could be therapeutic target for breast cancer treatment.
The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.
This work is fully supported by grants awarded to GG Xiao from the Bone Biology Program of the Cancer and Smoking Related Disease Research Program and the Nebraska Tobacco Settlement Biomedical Research Program (LB692, LB595 and LB506). This work was partially supported by OncomiR Biotechnologies Inc. (Los Angeles, CA, USA) to GG Xiao, and by National Institute of Health Grant DK84328 to Z Wang. We would like to thank Xintian Zhang and Lianguo Kang for technical help and fruitful discussion; Xianming Chen, Aiyu Gong and Guoku Hu for help with plasmid construct and luciferase assay.
- 30.Heo I, et al. (2008) Lin28 mediates the terminal uridylation of let-7 precursor microRNA. Mol. Cell 32:276–84.Google Scholar
- 33.Barh D, Parida S, Parida BP, Viswanathan G. (2008) Let-7, miR-125, miR-205, and miR-296 are prospective therapeutic agents in breast cancer molecular medicine. Gene Ther. Mol. Biolo. 12:189–206.Google Scholar